Medical Information

Lazertinib is an oral third-generation EGFR tyrosine kinase inhibitor mainly used for the treatment of EGFR mutant non-small cell lung cancer. It is important to pay attention to missed doses, dosage adjustments, and medication guidelines for special populations.

1. Drug Overview

(1) Lazotinib is an EGFR-TKI that can penetrate the blood-brain barrier, targeting T790M mutation and activated EGFR mutation, without affecting wild-type EGFR.

(2) The Korean version of the product is called LECLAZA, and the American version is Lazcluze. It was developed in 2018 by Yang Sen in collaboration with Korea's Yoo Han Trading Company.

2. Usage and dosage

(1) Recommended dose: Take 240mg orally once a day, in combination with bevacizumab. Swallow the entire tablet and do not chew.

(2) Omission treatment: Supplement can be taken within 12 hours, skip if it exceeds 12 hours, and take the medication according to the original plan next time.

3. Dose adjustment

(1) Gradually reduce adverse reactions: 240mg → 160mg → 80mg → discontinue medication.

(2) Liver and kidney dysfunction: Mild to moderate damage does not require adjustment, severe lack of data should be used with caution.

4. Medication precautions

(1) Overdose treatment: Stop medication immediately and receive supportive treatment. There is currently no specific antidote available.

(2) Characteristic: White film coated tablets, with light yellow markings after removing the coating.

5. Medication for special populations

(1) Elderly patients: No specific dose adjustment is required, but adverse reactions need to be monitored.

(2) Pregnancy and lactation: No clear data available, it is recommended to avoid pregnancy and lactation during treatment.